BKYI — BIO-key International, Inc.

Summary of BIO-key International's Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• 2025 Revenue: Decreased by 12% to $6.1 million from $6.9 million in 2024.
• Q4 2025 Revenue: License Fee revenue fell 26%, while Hardware revenue rose 85% and Service revenue decreased by 10%.
• Gross Margin: 77.5% in 2025, down from 81.4% in 2024, attributed to revenue mix changes.
• Net Loss: Increased to $4.6 million ($0.69 per share) for 2025, compared to a loss of $4.3 million ($2.09 per share) in 2024. Q4 net loss was $1.7 million ($0.19 per share).
• Cash Position: Ended 2025 with $2.7 million in cash, up from $438,000 in 2024. Book value increased to $7.6 million from $3.8 million.

2. Strategic Updates and Business Highlights

• Transitioned to selling only BIO-key-branded solutions in the EMEA region, which is expected to enhance gross margins and growth prospects.
• Launched the Defense & Intelligence Cybersecurity Initiative and introduced the EcoID III fingerprint scanner, aimed at regulated industries.
• Significant contract wins in the defense and financial sectors, with a notable $1 million license renewal from a foreign bank, reflecting a 30% increase.
• Approximately 50% of new U.S. business and nearly 100% of international business is generated through channel partners, including Amazon and TD Synnex.

3. Forward Guidance and Outlook

• Anticipates Q1 2026 revenue of approximately $2.2 million, a 37% increase over Q1 2025, with expectations of improved bottom line performance.
• The company aims for breakeven and profitability in 2026, supported by a strong cash position and ongoing cost management efforts.
• The global authentication solutions market is projected to grow significantly, with increasing demand for secure access to digital platforms.

4. Bad News, Challenges, or Points of Concern

• 2025 revenue performance was below expectations, primarily due to timing issues with a major contract renewal and the transition in the EMEA region.
• The gross margin decline reflects the impact of revenue mix, particularly with lower software license fees.
• The company faces competitive pressures in the authentication market, particularly from larger established players.
• There is a risk of needing a reverse stock split to maintain NASDAQ listing if the stock does not trade above $1 for 10 consecutive days.

5. Notable Q&A Insights

• Management clarified that the revenue decline in 2025 was largely due to the timing of contract renewals and the transition to BIO-key-only solutions.
• There is optimism about the first quarter of 2026, with expected revenue primarily from license fees and strong hardware sales.
• The company is seeing increased urgency from customers in regulated industries for enhanced security solutions.
• Future R&D expenses are expected to remain stable, with significant investments already made in the upcoming PortalGuard platform upgrade.
• The partnership with TD Synnex is viewed as a key growth driver, particularly in the public sector.

Overall, while BIO-key faced challenges in 2025, management expressed optimism for 2026, highlighting strategic initiatives and market trends that could drive growth and profitability.